We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein Nanoparticles Empower Potential Universal Flu Vaccine

By LabMedica International staff writers
Posted on 05 Feb 2018
A potential "universal" flu vaccine based on double-layered protein nanoparticles loaded with the invariable portion of viral hemagglutinin produced long-lasting immunity and fully protected mice against challenge with various strains of influenza A viruses.
 
Investigators at Georgia State University (Atlanta, USA) fabricated layered nanoparticles by inserting tetrameric M2e into protein nanoparticle cores and coating these cores with crosslinked headless hemagglutinin stalk proteins. More...
M2e (ectodomain of influenza matrix protein 2) is highly conserved in both human and avian influenza A viruses. The low immunogenicity against natural M2e can be overcome by fusing M2e to an appropriate carrier particle. Protein carriers with representative headless hemagglutinin of two different phylogenetic groups were constructed and purified.
 
The investigators reported in the January 24, 2018, online edition of the journal Nature Communications that vaccinations with the resulting protein nanoparticles in mice induced robust long-lasting immunity, fully protecting the mice against challenges by influenza A viruses of the same group or both groups.
 
"What we wanted to do is to induce responses to this stalk part of the influenza surface glycoprotein, not the head part," said senior author Dr. Bao-Zhong Wang, associate professor of biomedical sciences at Georgia State University. "This way you are protected against different viruses because all influenza viruses share this stalk domain. However, this stalk domain itself is not stable, so we used a very special way to make this vaccine construct with the stalk domain and had success. We assembled this stalk domain into a protein nanoparticle as a vaccine. Once inside, the nanoparticle can protect this antigenic protein so it will not be degraded. Our immune cells have a good ability to take in this nanoparticle, so this nanoparticle is much, much better than a soluble protein to induce immune responses. We are developing a universal influenza vaccine that would not need to change the vaccine type every year because it is universal and can protect against any influenza virus."
 
In addition to their role in a universal flu vaccine, the physiologically activated disassembly of the protein nanoparticles after uptake into cells implies a wide potential for protein drug delivery and controlled release.
 

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.